Inhibikase Therapeutics (NYSE:IKT) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Inhibikase Therapeutics (NYSE:IKTFree Report) in a research note issued to investors on Friday morning,Benzinga reports. The brokerage issued a buy rating and a $8.00 target price on the stock.

Separately, HC Wainwright dropped their price target on shares of Inhibikase Therapeutics from $15.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, October 14th.

Read Our Latest Stock Report on Inhibikase Therapeutics

Inhibikase Therapeutics Stock Performance

NYSE:IKT opened at $2.88 on Friday. Inhibikase Therapeutics has a 52-week low of $0.80 and a 52-week high of $3.82. The firm’s 50-day moving average is $1.72 and its 200-day moving average is $1.57.

Inhibikase Therapeutics (NYSE:IKTGet Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). Sell-side analysts forecast that Inhibikase Therapeutics will post -0.4 earnings per share for the current year.

Insider Buying and Selling at Inhibikase Therapeutics

In other news, Director Arvind Kush bought 145,000 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The stock was acquired at an average price of $1.37 per share, for a total transaction of $198,650.00. Following the transaction, the director now directly owns 145,000 shares of the company’s stock, valued at $198,650. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 14.70% of the company’s stock.

Institutional Investors Weigh In On Inhibikase Therapeutics

A hedge fund recently bought a new stake in Inhibikase Therapeutics stock. Armistice Capital LLC bought a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKTFree Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 589,575 shares of the company’s stock, valued at approximately $713,000. Armistice Capital LLC owned approximately 8.17% of Inhibikase Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 3.81% of the stock is owned by hedge funds and other institutional investors.

About Inhibikase Therapeutics

(Get Free Report)

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.

Featured Articles

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.